Zevra/Acer merger supplement filed; shareholder lawsuits prompt additional disclosures

ZEVRA THERAPEUTICS, INC.

Three stockholder lawsuits filed (S.D.N.Y. and D. Del.) alleging proxy omissions; demand letters received.
Acer voluntarily supplements proxy statement on Oct. 30 to address litigation risks, without admitting materiality.
Supplement adds details: no standstill provisions in confidentiality agreements, no officer/director employment offers from Zevra.
Updated financial analyses: DCF terminal growth rate of -80%; implied equity values $0.90-$2.71 (Plan 1) and $1.13-$3.63 (Plan 2).
Acer board continues to unanimously recommend stockholder vote 'FOR' the merger at Nov. 8 special meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.